Wegovy and Insomnia: What's Really Going On at Night

Three weeks in, wide awake at 3am — here's what patients often describe

You've started Wegovy, you're a few weeks into treatment, and sleep that used to come easily now feels out of reach. You lie awake, mind busier than usual, or you drop off fine and wake in the small hours. It's unsettling, and the obvious question is whether the injection is behind it.

The honest answer is: possibly, but probably not in a simple, direct way. Wegovy's Summary of Product Characteristics (the document clinicians and pharmacists use rather than the shorter patient leaflet) lists 'insomnia' under uncommon adverse reactions. Uncommon means it was reported in fewer than 1 in 100 trial participants. That's real, and worth acknowledging. But it sits well below the common effects, most of which are gastrointestinal: nausea, vomiting, constipation, indigestion and reflux appear in studies far more frequently than sleep complaints do. If you're waking because of reflux or nausea, the culprit is the GI effect, not some direct action on your sleep centres. Worth separating the two.

There's also a timing pattern that comes up in clinical conversation. Sleep complaints on Wegovy tend to cluster in the weeks immediately after a dose increase, then ease off as the body adjusts. The semaglutide overview explains how the titration schedule works across the dosing ladder, which may help contextualise when and why symptoms shift.

Why the weight-loss process itself can alter sleep

One thing that often gets missed in discussions about does Wegovy give you insomnia: significant weight loss changes sleep, full stop. That's not a criticism, it's physiology. As body fat reduces, appetite hormones like leptin and ghrelin shift. Ghrelin, which promotes hunger, also has roles in sleep regulation, and changes in its levels during active weight loss may affect sleep quality transiently. This is seen across multiple effective weight-loss interventions, not just GLP-1 medicines.

Separately, if someone was experiencing obstructive sleep apnoea before starting treatment (which is common in people living with obesity) the condition may actually improve as weight comes off. But the transition period can involve unusual sleep patterns before apnoea fully resolves. So some people report sleeping worse initially, then considerably better over time.

Rapid calorie reduction alongside treatment can also be a factor. Eating less, particularly in the early weeks when nausea suppresses appetite significantly, can affect energy balance in ways that touch sleep. Keeping protein intake adequate and staying hydrated matters for more than just muscle; it keeps the whole system more stable, and our page on the rise of Wegovy face and sarcopenia explains why protecting muscle mass during active weight loss deserves close attention. Our Wegovy treatment page covers the lifestyle context that works alongside the medicine.

Does Wegovy directly cause insomnia, and what does the trial data say

The STEP 1 trial, which enrolled over 1,900 adults with obesity and ran for 68 weeks, is the main evidence base for Wegovy at 2.4mg. Sleep disturbance was not a primary or secondary endpoint in that trial, so the data is less granular than the headline weight-loss figures. What the NHS medicines information for semaglutide confirms is that difficulty sleeping can occur but is not among the commonly reported effects. The MHRA's prescribing documentation draws the same line.

There's a common misconception that stimulant-type effects explain the insomnia, people sometimes assume GLP-1 medicines work like appetite suppressants that rev the nervous system. They don't. Semaglutide acts primarily in the gut and brain areas involved in satiety and blood-sugar regulation; it is not a stimulant. That misconception can be set aside gently. For anyone curious about how the medicine is produced and quality-assured, our Wegovy laboratorio page covers the manufacturing background in more detail.

For anyone wondering about wegovy and insomnia in the context of a longer-term pattern rather than the adjustment weeks, it's worth knowing that the MHRA's Yellow Card scheme exists precisely for this: patients and clinicians can report any suspected side effect, and those reports shape ongoing safety monitoring. If something feels persistent or worsening, reporting it is both useful and straightforward. Our team is also reachable through the contact page for anything that needs a quicker conversation.

When to tell your prescriber and what they might consider

A few nights of broken sleep after a dose increase is different from two months of severe insomnia. Most prescribers would want to hear about the latter, for two practical reasons. First, it might not be Wegovy at all, stress, anxiety, underlying conditions or other medications can all cause insomnia independently, and it would be a mistake to adjust a medicine that is otherwise working well if something else is driving the problem. Second, if the timing strongly suggests Wegovy is involved, there are sensible options: slowing the titration pace, reviewing injection timing, or simply waiting through an adjustment phase that may resolve on its own. It is also worth being aware that some patients report heightened skin sensitivity during treatment, and our page on allodynia caused by Wegovy explores how that nerve-related discomfort can emerge and what to do about it.

Injection timing occasionally comes up in these discussions. Some people find moving their once-weekly injection to a different day of the week makes a small practical difference to when any GI discomfort peaks relative to sleep. That kind of fine-tuning is a conversation for your prescriber, not something to adjust independently. The guide to inserting Wegovy covers technique and site rotation, which is a separate but related piece of self-management worth having right.

If you're considering starting treatment and want to discuss how side effects including sleep changes are monitored, checking what's included as part of your care matters. Start your free consultation with our prescribers, who review every patient personally and remain available seven days a week for ongoing support.